(Reuters) -GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker’s asthama drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
COPD causes restricted airflow and breathing problems and is also known as ‘smoker’s lungs’ because in Western countries, it primarily affects cigarette smokers.
(Reporting by Anandita Mehrotra in Bengaluru; Editing by Mrigank Dhaniwala)
